NYSE:PBHPrestige Consumer Healthcare Competitors & Alternatives

Prestige Consumer Healthcare (NYSE:PBH) and Ascendis Pharma A/S (NASDAQ:ASND) are both consumer discretionary companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Prestige Consumer Healthcare and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Risk and Volatility

Prestige Consumer Healthcare has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

100.0% of Ascendis Pharma A/S shares are held by institutional investors. 1.2% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Prestige Consumer Healthcare and Ascendis Pharma A/S's top-line revenue, earnings per share (EPS) and valuation.

Prestige Consumer Healthcare has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Prestige Consumer Healthcare and Ascendis Pharma A/S, as provided by MarketBeat.

Prestige Consumer Healthcare presently has a consensus target price of $66.8333, indicating a potential upside of 87.68%. Ascendis Pharma A/S has a consensus target price of $172.2727, indicating a potential upside of 25.77%. Given Prestige Consumer Healthcare's higher possible upside, equities research analysts clearly believe Prestige Consumer Healthcare is more favorable than Ascendis Pharma A/S.

Summary

Prestige Consumer Healthcare beats Ascendis Pharma A/S on 8 of the 14 factors compared between the two stocks.

Prestige Consumer Healthcare (NYSE:PBH) and Bausch Health Companies (NYSE:BHC) are both consumer discretionary companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Earnings and Valuation

This table compares Prestige Consumer Healthcare and Bausch Health Companies' gross revenue, earnings per share (EPS) and valuation.

Prestige Consumer Healthcare has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prestige Consumer Healthcare and Bausch Health Companies' net margins, return on equity and return on assets.

Volatility & Risk

Prestige Consumer Healthcare has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Prestige Consumer Healthcare and Bausch Health Companies, as provided by MarketBeat.

Prestige Consumer Healthcare presently has a consensus target price of $66.8333, suggesting a potential upside of 87.68%. Bausch Health Companies has a consensus target price of $30.9412, suggesting a potential upside of 80.42%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Bausch Health Companies.

Institutional and Insider Ownership

68.9% of Bausch Health Companies shares are owned by institutional investors. 1.2% of Prestige Consumer Healthcare shares are owned by company insiders. Comparatively, 12.1% of Bausch Health Companies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Bausch Health Companies beats Prestige Consumer Healthcare on 9 of the 14 factors compared between the two stocks.

PPD (NASDAQ:SDGR) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.

Insider and Institutional Ownership

34.9% of PPD shares are owned by institutional investors. 1.2% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for PPD and Prestige Consumer Healthcare, as reported by MarketBeat.com.

PPD currently has a consensus price target of $59.6667, suggesting a potential downside of 35.40%. Prestige Consumer Healthcare has a consensus price target of $66.8333, suggesting a potential upside of 87.68%. Given Prestige Consumer Healthcare's higher possible upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than PPD.

Profitability

This table compares PPD and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares PPD and Prestige Consumer Healthcare's gross revenue, earnings per share (EPS) and valuation.

Prestige Consumer Healthcare has higher revenue and earnings than PPD.

Summary

Prestige Consumer Healthcare beats PPD on 7 of the 10 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Volatility and Risk

Jazz Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Profitability

This table compares Jazz Pharmaceuticals and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Jazz Pharmaceuticals and Prestige Consumer Healthcare's revenue, earnings per share (EPS) and valuation.

Jazz Pharmaceuticals has higher revenue and earnings than Prestige Consumer Healthcare. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jazz Pharmaceuticals and Prestige Consumer Healthcare, as provided by MarketBeat.

Jazz Pharmaceuticals currently has a consensus target price of $157.1765, indicating a potential upside of 47.45%. Prestige Consumer Healthcare has a consensus target price of $66.8333, indicating a potential upside of 87.68%. Given Prestige Consumer Healthcare's higher probable upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Jazz Pharmaceuticals.

Insider and Institutional Ownership

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Jazz Pharmaceuticals beats Prestige Consumer Healthcare on 12 of the 14 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

Profitability

This table compares Ultragenyx Pharmaceutical and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ultragenyx Pharmaceutical and Prestige Consumer Healthcare's gross revenue, earnings per share (EPS) and valuation.

Prestige Consumer Healthcare has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Ultragenyx Pharmaceutical and Prestige Consumer Healthcare, as provided by MarketBeat.

Ultragenyx Pharmaceutical currently has a consensus target price of $81.3571, indicating a potential downside of 5.68%. Prestige Consumer Healthcare has a consensus target price of $66.8333, indicating a potential upside of 87.68%. Given Prestige Consumer Healthcare's higher possible upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Ultragenyx Pharmaceutical.

Volatility and Risk

Ultragenyx Pharmaceutical has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Prestige Consumer Healthcare beats Ultragenyx Pharmaceutical on 8 of the 14 factors compared between the two stocks.

Zai Lab (NASDAQ:ZLAB) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Zai Lab and Prestige Consumer Healthcare, as reported by MarketBeat.com.

Zai Lab currently has a consensus price target of $81.25, suggesting a potential downside of 6.58%. Prestige Consumer Healthcare has a consensus price target of $66.8333, suggesting a potential upside of 87.68%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Zai Lab.

Profitability

This table compares Zai Lab and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Zai Lab and Prestige Consumer Healthcare's revenue, earnings per share and valuation.

Prestige Consumer Healthcare has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

78.3% of Zai Lab shares are owned by institutional investors. 1.2% of Prestige Consumer Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Zai Lab has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Summary

Prestige Consumer Healthcare beats Zai Lab on 9 of the 14 factors compared between the two stocks.